EVNIN LUKE 4
4 · Werewolf Therapeutics, Inc. · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
Werewolf Therapeutics (HOWL) Director Luke Evnin Sells Shares
What Happened
Luke Evnin, a director (via affiliated investment vehicles), reported the sale of 139,803 Werewolf Therapeutics (HOWL) shares in three open‑market transactions on June 1–3, 2026. The trades generated aggregate proceeds of roughly $63,629 (80,459 shares for $37,816 on 6/1; 29,595 shares for $13,318 on 6/2; 29,749 shares for $12,495 on 6/3). These were sales (code S) and not purchases — sales are often routine and do not necessarily indicate company outlook.
Key Details
- Dates & reported prices:
- 2026-06-01: 80,459 shares at $0.47 (reported) — proceeds $37,816. (Footnote: weighted‑average and per-trade prices ranged; see filing.)
- 2026-06-02: 29,595 shares at $0.45 — proceeds $13,318. (Weighted‑average; range noted in footnotes.)
- 2026-06-03: 29,749 shares at $0.42 — proceeds $12,495. (Weighted‑average; range noted in footnotes.)
- Sales were executed by affiliated entities: MPM Asset Management LLC (AM LLC), MPM BioVentures 2014 (BV 2014), BV 2014(B), AM BV2014, and MPM Oncology Innovations Fund (MPM OIF). Each day's sale is broken down across those entities in the filing.
- Remaining reported holdings (across the related entities) after these transactions: the filing lists per-entity totals (final aggregate shown in the filing: 54,910; 346,707; 23,123; 11,931; and 75,854 shares for the five entities, respectively — see filing for the detailed per-entity breakdown).
- Footnotes of note:
- Transactions were effected pursuant to a Rule 10b5‑1 trading plan dated March 26, 2026.
- Reported prices are weighted averages; the filing provides price ranges and offers to supply the per‑trade pricing on request.
- The reporting person (Luke Evnin) is a member/manager/director of the listed entities and disclaims direct beneficial ownership except to the extent of any pecuniary interest.
- Filing timeliness: the report was filed with an accession date of 2026-06-03 for transactions through 2026-06-01–06-03; no late‑filing notation is indicated in the summary provided here.
Context
- These sales were done by affiliated investment vehicles rather than direct, personal one-off trades. Footnotes show institutional holdings and Evnin’s managerial roles; he disclaims beneficial ownership except for pecuniary interest.
- Because the trades were executed under a 10b5‑1 plan, they were pre‑scheduled, which is a common mechanism to avoid timing accusations; this is factual information, not a statement about motivation.
Insider Transaction Report
Form 4
EVNIN LUKE
Director
Transactions
- Sale
Common Stock
[F1][F2][F3][F4][F5]2026-06-01$0.47/sh−80,459$37,816→ 542,120 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F6][F7][F4][F8]2026-06-02$0.45/sh−29,595$13,318→ 512,525 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F9][F10][F4][F11]2026-06-03$0.42/sh−29,749$12,495→ 482,776 total(indirect: See Footnotes)
Footnotes (11)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.42 to $0.4367 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The shares are held as follows: 51,723 by AM LLC, 326,583 by BV 2014, 21,781 by BV 2014(B), 11,238 by AM BV2014 and 71,451 by MPM OIF.
- [F2]The shares were sold as follows: 8,620 by MPM Asset Management LLC ("AM LLC"), 54,428 by MPM BioVentures 2014, L.P. ("BV 2014"), 3,630 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,873 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 11,908 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- [F5]The shares are held as follows: 58,081 by AM LLC, 366,727 by BV 2014, 24,458 by BV 2014(B), 12,620 by AM BV2014 and 80,234 by MPM OIF.
- [F6]The shares were sold as follows: 3,171 by AM LLC, 20,020 by BV 2014, 1,335 by BV 2014(B), 689 by AM BV2014 and 4,380 by MPM OIF.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4304 to $0.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The shares are held as follows: 54,910 by AM LLC, 346,707 by BV 2014, 23,123 by BV 2014(B), 11,931 by AM BV2014 and 75,854 by MPM OIF.
- [F9]The shares were sold as follows: 3,187 by AM LLC, 20,124 by BV 2014, 1,342 by BV 2014(B), 693 by AM BV2014 and 4,403 by MPM OIF.
Signature
/s/ Luke Evnin|2026-06-03